<- Go Home
Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Market Cap
$424.1M
Volume
75.7K
Cash and Equivalents
$20.3M
EBITDA
-$4.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$20.6M
Profit Margin
59.30%
52 Week High
$18.41
52 Week Low
$3.03
Dividend
N/A
Price / Book Value
26.54
Price / Earnings
-77.26
Price / Tangible Book Value
41.88
Enterprise Value
$408.2M
Enterprise Value / EBITDA
-99.82
Operating Income
-$5.2M
Return on Equity
33.35%
Return on Assets
-9.68
Cash and Short Term Investments
$20.3M
Debt
$4.3M
Equity
$16.0M
Revenue
$34.7M
Unlevered FCF
$660.1K
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium